This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ibrahim, A. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Ibrahim, A. Articles by Pazdur, R.

FDA Drug Approval Summaries: Oxaliplatin

Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA

Correspondence: Amna Ibrahim, M.D., Food and Drug Administration, HFD-150, 5600 Fishers Lane, Rockville, Maryland 20857, USA. Telephone: 301-594-2473; Fax: 301-594-0499; e-mail: IbrahimA{at}cder.fda.gov

The purpose of this report is to summarize information on oxaliplatin, a drug recently approved by the U.S. Food and Drug Administration. Information provided includes regulatory history, study design, efficacy and safety results, and pertinent literature references.

A single, multicenter, randomized trial, enrolling 463 patients with metastatic colorectal carcinoma whose disease had recurred or progressed during or within 6 months of completion of therapy with the combination of bolus 5-fluorouracil (FU)/leucovorin (LV) and irinotecan, was submitted. Study arms included infusional 5-FU/LV alone (arm A), oxaliplatin alone (arm B), and the combination of oxaliplatin and infusional 5-FU/LV(arm C). Oxaliplatin, at a dose of 85 mg/m², was administered to patients in arms B and C intravenously over 2 hours in 250–500 ml of dextrose 5% in water (D5W) on day 1 only. A 200-mg/m² dose of LV was administered simultaneously to arm C patients, in a separate bag using a Y-line, or alone to arm A patients, by i.v. infusion, over 2 hours. 5-FU was then administered to arms A and C patients, first as a bolus injection over 2–4 minutes at a dose of 400 mg/m², then as a continuous infusion in 500 ml of D5W over 22 hours at a dose of 600 mg/m². LV was repeated on day 2 of the cycle (arms A and C) followed by a 400-mg/m² 5-FU bolus and a 600-mg/m² 22-hour infusion. Treatment was repeated every 2 weeks.

Response rate was the prespecified end point for accelerated approval. Time to progression (TTP) was a secondary end point. The prespecified primary comparison was between the 5-FU/LV regimen and the 5-FU/LV/ oxaliplatin combination regimen. The three arms were well balanced for patient prognostic factors.

There were no complete responders. The partial response rates were 0%, 1%, and 9% for the 5-FU/LV, oxaliplatin, and oxaliplatin plus 5-FU/LV treatments, respectively (p = 0.0002, arm C versus arm A). The median times to radiographic tumor progression, based on available radiographs, were 2.7 months, 1.6 months, and 4.6 months, respectively (p < 0.0001, arm C versus arm A).

Common adverse events associated with the combination treatment included peripheral neuropathy, fatigue, diarrhea, nausea, vomiting, stomatitis, and abdominal pain. Neutropenia was the major hematologic toxicity. Adverse events were similar in men and women and in patients <65 and 65 years of age, but older patients may have been more susceptible to dehydration, diarrhea, hypokalemia, and fatigue.

Oxaliplatin in combination with infusional 5-FU/LV was approved for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first-line therapy with the combination of bolus 5-FU/LV and irinotecan. Approval was based on response rate and on an interim analysis of TTP. No results are available, at this time, that demonstrate a clinical benefit, such as improvement in disease-related symptoms or survival.

Key Words. Oxaliplatin • Metastatic colorectal cancer • Second-line treatment

This article has been cited by other articles:

				S. R. McWhinney, R. M. Goldberg, and H. L. McLeod Platinum neurotoxicity pharmacogenetics Mol. Cancer Ther., January 1, 2009; 8(1): 10 - 16. [Abstract] [Full Text] [PDF]

				T. Matsumura, K. Yuji, T. Nakamura, F. Beppu, E. Kusumi, T. Hamaki, K. Kobayashi, Y. Kishi, M. Onishi, Y. Kodama, et al. Possible Impact of the NHK Special Questioning Cancer Treatment in Japan on Clinicians' Prescriptions of Oxaliplatin Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 78 - 83. [Abstract] [Full Text] [PDF]

				P. Kokhaei, A. O. Abdalla, L. Hansson, E. Mikaelsson, M. Kubbies, A. Haselbeck, H. Jernberg-Wiklund, H. Mellstedt, and A. Osterborg Expression of Erythropoietin Receptor and In vitro Functional Effects of Epoetins in B-Cell Malignancies Clin. Cancer Res., June 15, 2007; 13(12): 3536 - 3544. [Abstract] [Full Text] [PDF]

				L. Li, B. Ahmed, K. Mehta, and R. Kurzrock Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer Mol. Cancer Ther., April 1, 2007; 6(4): 1276 - 1282. [Abstract] [Full Text] [PDF]

				S. S. Jacobs, E. Fox, C. Dennie, L. B. Morgan, C. L. McCully, and F. M. Balis Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates Clin. Cancer Res., February 15, 2005; 11(4): 1669 - 1674. [Abstract] [Full Text] [PDF]

				R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur Accelerated Approval of Oncology Products: A Decade of Experience J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509. [Abstract] [Full Text] [PDF]